Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
GMGenmab A/S logo

Genmab A/S (GMAB)

NASDAQ Global Select · Currency in USD
$43.79 ▲ +3.79 (+9.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$43.90 ▲ +0.11 (+0.25%)
After hours: Oct 23, 7:40 PM ET

Summary

Previous Close
$40.00
Open
$39.83
Day's Range
$39.64 – $44.34
52 Week Range
$23.62 – $44.34
Volume
13,000,825
Avg. Volume
2,851,800
Market Cap
$26.93B
Beta (5Y Monthly)
0.65
PE Ratio (TTM)
30.96
EPS (TTM)
$1.29
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$44.20

Profile: Genmab A/S

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3,119
CEO
Jan van de Winkel
Website
genmab.com

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.37 · Revenue est. $1.20B
DateEst.Actual
Aug 6, 2026$0.37$0.54Beat
May 7, 2026$0.15$0.09Miss
Feb 17, 2026$0.46$0.05Miss
Nov 6, 2025$0.48$0.65Beat
Aug 7, 2025$0.39$0.54Beat
May 8, 2025$0.23$0.31Beat

Analyst view

Consensus price target
$44.20 ▲ +0.9%
Range $38.00 – $58.00
Rating: Buy
Buy 72% · Hold 22% · Sell 6%

Get free alerts on GMAB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.